Acute Kidney Injury
Conditions
Brief summary
Acute kidney injury is associated with worsened outcome for critically ill patients. Sepsis-associated and non-septic cardiothoracic surgery associated AKI have been reported, nonetheless, precise pathomechanistic differences as well as detectability of transcriptional and proteomic changes in correlation with imaging and plasma markers are unclear.
Detailed description
Acute kidney injury is a common and detrimental finding in critically ill/sepsis patients as well as non-septic patients post cardiothoracic surgery. In many cases renal replacement therapy is required and an acute kidney injury is linked to increased morbidity and mortality in intensive care patients. Using routinely obtained clinical samples as well as imaging data, this observational trial investigates the transcriptomic and proteomic determinants detectable in septic and non-septic AKI patient subsets and their correlation with outcome and AKI diagnostic parameters.
Interventions
OTHERNo study-specific interventions
Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
Sponsors
University Hospital Muenster
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 150 Years
Inclusion criteria
* Inclusion criteria: * study consent; * KDIGO\>=2; * vasoplegia and/or sepsis or elective nephrectomy. *
Exclusion criteria
* Age\<18 years; * pregnancy/nursing; * preexisting CKD with eGFR\<60m/min; * dialysis; former ogran transplantation; * HIV; hematologic malignancies; * immunsuppression; * 4h post biopsy non-pausable effective anticoagulation; * pre-existing coagulopathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of transcriptional and proteomic gene regulation in tissue with clinical molecular Imaging and AKI biomarkers. | Through study completion, an average of 1 year. | Proteomic and RNAseq-based multi-omics pattern recognition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Further organ failure based on systemic assessment | Through study completion, an average of 1 year. | Occurrence of organ failure based on hospital data including routinely applied scores, laboratory values or clinical examination. |
| RRT incidence | 28 days | incidence of renal replacement therapy |
| ICU length of stay | Through study completion, an average of 1 year. | Length of stay for ICU |
| Hospital length of stay | Through study completion, an average of 1 year. | Hospital length of stay |
| Mortality | 28 day | 28 day mortality |
Contacts
Primary ContactAlexander Zarbock, MD
Backup ContactAndreas Margraf, MD
Outcome results
None listed